Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · see citing works

Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms

Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294 · see citing works

Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis

Akin, C., Scott, L. M., Kocabas, C. N., Kushnir-Sukhov, N., Brittain, E., Noel, P., & Metcalfe, D. D. (2007) · Blood · doi:10.1182/blood-2006-06-028100 · Cited by 240 · see citing works

Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis

Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · see citing works

Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome

Sonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000096442 · Cited by 129 · see citing works

Anti-IgE as a mast cell–stabilizing therapeutic agent

Chang, T. W., & Shiung, Y.-Y. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.04.005 · Cited by 123 · see citing works

Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

Douglass, J. A., Carroll, K., Voskamp, A. L., Bourke, P., Wei, A. H., & O’Hehir, R. E. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02259.x · Cited by 66 · see citing works

Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases

Molderings, G. J., Raithel, M., Kratz, F., Azémar, M., Haenisch, B., Harzer, S., & Homann, J. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4640 · Cited by 63 · see citing works

Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab

Bell, M. C., & Jackson, D. J. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.02.021 · Cited by 50 · see citing works

Omalizumab monotherapy for bee sting and unprovoked “anaphylaxis” in a patient with systemic mastocytosis and undetectable specific IgE

Kontou-Fili, K., Filis, C. I., Voulgari, C., & Panayiotidis, P. G. (2010) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2010.04.011 · Cited by 47 · see citing works

Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers

Jiménez‐Rodriguez, T. W., Garcia-Neuer, M. I., Alenazy, L. A., & Castells, M. (2018) · Journal of Asthma and Allergy · doi:10.2147/jaa.s159411 · Cited by 152 · see citing works

Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management

Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135 · see citing works

Off-Label Uses of Omalizumab

El‐Qutob, D. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8490-y · Cited by 97 · see citing works

Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83 · see citing works

Mast Cell Activation Syndrome

Frieri, M. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8487-6 · Cited by 65 · see citing works

Anaphylaxis

Bilò, M. B., Martini, M., Tontini, C., Corsi, A., & Antonicelli, L. (2020) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.158 · Cited by 47 · see citing works

A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis

Carter, M. C., Marić, I., Brittain, E., Bai, Y., Lumbard, K., Bolan, H., Cantave, D., Scott, L. M., & Metcalfe, D. D. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.005 · Cited by 38 · see citing works

Phenotypes, endotypes and biomarkers in anaphylaxis: current insights

Sala-Cunill, A., Guilarte, M., & Cardona, V. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000472 · Cited by 36 · see citing works

Risk factors and treatment of refractory anaphylaxis - a review of case reports

Francuzik, W., Dölle-Bierke, S., & Worm, M. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1450140 · Cited by 25 · see citing works

Mastocytosis

Abid, A., Malone, M. A., & Curci, K. M. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.04.007 · Cited by 24 · see citing works

IgE and non-IgE-mediated pathways in anaphylaxis

Worm, M., Pažur, K., Morakabati, P., & Redhu, D. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01056-7 · Cited by 23 · see citing works

Gastrointestinal Involvement in Mast Cell Activation Disorders

Hsieh, F. H. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.008 · Cited by 17 · see citing works

Successful treatment of idiopathic mast cell activation syndrome with low-dose omalizumab

Berry, R., Hollingsworth, P., & Lucas, M. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1075 · Cited by 15 · see citing works

Cardiovascular symptoms in patients with systemic mast cell activation disease

Kolck, U. W., Haenisch, B., & Molderings, G. J. (2015) · Translational research · doi:10.1016/j.trsl.2015.12.012 · Cited by 10 · see citing works

Efficacy of Omalizumab in Indolent Systemic Mastocytosis

Slapnicar, C., Trinkaus, M., Hicks, L., & Vadas, P. (2019) · Case Reports in Hematology · doi:10.1155/2019/3787586 · Cited by 16 · see citing works

Differential Diagnosis of Chronic Urticaria and Angioedema Based on Molecular Biology, Pharmacology, and Proteomics

Dreyfus, D. H. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.010 · Cited by 8 · see citing works

Mast cell disorders

Chen, M., Kim, A., Zuraw, B. L., Doherty, T. A., & Christiansen, S. C. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.03.027 · Cited by 7 · see citing works

Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome

Matheny, M. V., Craig, T., & Al‐Shaikhly, T. (2024) · Allergy and Asthma Proceedings · doi:10.2500/aap.2025.46.240076 · Cited by 6 · see citing works

The roles of mast cells in allergic inflammation and mast cell-related disorders

Kim, H.-K. (2017) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2017.5.5.248 · Cited by 5 · see citing works

New treatments for systemic mastocytosis in 2025

Costanzo, G., Marzio, V., Cavaglià, E., Paoletti, G., & Heffler, E. M. (2025) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001079 · Cited by 4 · see citing works

Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series

Caminati, M., Olivieri, E., Nalin, F., Zanotti, R., Senna, G., Schiappoli, M., Dama, A., & Bonadonna, P. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.11.010 · Cited by 4 · see citing works

Human(ized) monoclonal antibodies in atopic patients – state of the art

Yalçın, A. D., Onbaşı, K., Uzun, R., Herth, F. J. F., & Schnabel, P. A. (2020) · Central European Journal of Immunology · doi:10.5114/ceji.2020.97909 · Cited by 2 · see citing works

Cardiovascular manifestations in mast cell activation disease: key insights for cardiologists and angiologists

Taumann, W., & Molderings, G. J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1705201 · Cited by 1 · see citing works

Anaphylaxis in Pregnancy

Calabria, C. W., & Coop, C. A. (2018) · Springer eBooks · doi:10.1007/978-3-030-03395-8_6 · Cited by 1 · see citing works

Management of Anaphylaxis Refractory to Standard First Line Therapy

Hammond, C. M., & Lieberman, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-43205-8_3

Humanized Monoclonal Antibodies in Pulmonology: An Integrated Review

(2017) · Internal Medicine Research – Open Journal · doi:10.31038/imroj.2017213

Mast Cells in Connective Tissue Regulation and Altered Regulation in Hypermobility Ehlers-Danlos Syndrome (hEDS): Why the Association of Mast Cell Activation Syndrome and hEDS?

Hart, D. A. (2026) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2026.194013

Omalizumab For a Case Of Monoclonal Mast Cell Activation Syndrome With Recurrent Anaphylaxis

Jagdis, A., & Vadas, P. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.121 · Cited by 2 · see citing works

Expanding Spectrum of Mast Cell Activation Disorders: Monoclonal and Idiopathic Mast Cell Activation Syndromes

Picard, M., Junior, P. F. G.-B., Mezzano, V., & Castells, M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.001 · Cited by 77 · see citing works

Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab

Bell, M. C., & Jackson, D. J. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.02.021 · Cited by 50 · see citing works

[NON-CLONAL MAST CELL ACTIVATION SYNDROME: DESCRIPTION OF SERIES OF PATIENTS, DIAGNOSTIC CRITERIA AND TREATMENT].

Confino‐Cohen, R., & Mekori, Y. A. (2015) · PubMed

Síndrome de activación mastocitaria. A propósito de un caso clínico

Cardona, R., Muñoz, M., Gómez-Henao, C., Díez-Zuluaga, L. S., & Gálvez, K. (2019) · Revista Alergia México · doi:10.29262/ram.v66i4.587